Skip to main content
. Author manuscript; available in PMC: 2014 Jun 16.
Published in final edited form as: Int J Oncol. 2012 Mar 19;40(6):1858–1864. doi: 10.3892/ijo.2012.1407

Figure 1.

Figure 1

Molecular characterization of MCF-7 cells harboring constitutive activation of Raf/MEK/MAPK pathway. (A) Immunoblot assay showing MAPK phosphorylation in vMCF-7ΔRaf-1 compared to parental MCF-7 cells. (B) Cell cycle analysis (FACS) showing increased S phase fraction in vMCF-7ΔRaf-1 compared to parental MCF-7 cells. (C) MTT assay and FACS analysis of variants and parental MCF-7 cells treated with chemo-endocrine therapy. (D) Real-time cell migration assay showing higher motility of vMCF-7ΔRaf-1 compared to parental MCF-7 cells.